Summary & Overview
HCPCS J1443: Ferric Pyrophosphate Citrate Injection, 0.1 mg
HCPCS Level II code J1443 identifies injection of ferric pyrophosphate citrate solution (Triferic), dosed at 0.1 mg of elemental iron per unit. This code is used to bill parenteral administration of a specialized iron therapy often employed in patients requiring intravenous iron replacement. Nationally, accurate coding for parenteral iron products affects coverage determinations, site-of-care billing, and utilization tracking for anemia management.
Key payers covered in this profile include Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare. Readers will find a concise overview of the clinical context for J1443, typical places of service, and which stakeholders commonly manage reimbursement. The publication outlines benchmark elements typically examined for such codes (payment considerations, site-of-service distinctions, and common billing modifiers) and highlights relevant policy or coverage topics that influence access and claim adjudication.
This summary equips revenue cycle professionals, clinicians, and policy analysts with a clear understanding of what J1443 represents, why precise coding matters for program integrity and patient access, and which aspects of billing and policy to review when working with parenteral iron therapies.
Billing Code Overview
HCPCS Level II code J1443 describes an injection of ferric pyrophosphate citrate solution (Triferic), with each unit representing 0.1 mg of elemental iron. This code is used to report administration of a parenteral iron formulation intended for clinical use in settings where intravenous or infusion therapy is provided.
Service type: Parenteral iron infusion/injection
Typical site of service: Infusion center, outpatient clinic, hospital outpatient department, or dialysis facility depending on clinical protocol and payer rules.
Clinical & Coding Specifications
Clinical Context
A 58-year-old patient with end-stage renal disease (ESRD) on maintenance hemodialysis presents for routine dialysis therapy and requires iron repletion to maintain hemoglobin and reduce ESA (erythropoiesis-stimulating agent) requirements. The patient receives J1443 (ferric pyrophosphate citrate solution, 0.1 mg of iron) administered via the dialysate or intravenous infusion during the hemodialysis session per facility protocol. The clinical workflow includes verification of the dialysis order, medication reconciliation, confirmation of recent hemoglobin and iron studies (serum ferritin, transferrin saturation), nursing preparation and administration of the ferric pyrophosphate citrate product, monitoring for infusion reactions during dialysis, documentation of lot number and dose, and billing using the J1443 HCPCS Level II code. Typical sites of service are hospital outpatient dialysis units and independent dialysis clinics. Typical patient presentation includes chronic anemia of kidney disease with laboratory evidence supporting parenteral iron therapy and ongoing hemodialysis treatment.
Coding Specifications
| Modifier | Description | When to Use |
|---|---|---|
22 | Increased procedural services | When work required to deliver the medication is substantially greater than typical (e.g., unusually complex access or prolonged infusion preparation) and supported by documentation. |